Compare Quest Diagnostics Inc (DGX) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs ProShares Ultra QQQ ETF — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.24B), while ProShares Ultra QQQ ETF trades at $92.67. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while ProShares Ultra QQQ ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals.
| DGX | QLD | |
|---|---|---|
Market Cap | $26.24B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $238.50 | $100.53 |
52-Week Low | $173.49 | $57.16 |
Enterprise Value | $32.00B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
QLD, the ProShares Ultra QQQ ETF, trades at $92.32, up 0.75% today, reflecting a bullish technical stance with moving averages signaling strength. The fund offers 2x daily leveraged exposure to the Nasdaq-100 index, having delivered over 10,000% total return since inception. Recent institutional buying includes 180 Wealth Advisors increasing its stake by 29.4% in Q2 2026 (SEC Form 13F filing, August 6, 2026).
Outlook remains tied to tech sector performance, with AI optimism and easing geopolitical tensions cited as tailwinds (Zacks Investment Research, May 29, 2026). Key risks include leveraged ETF decay and volatility, evidenced by a 63.80% historical maximum drawdown. The neutral oscillator reading suggests near-term consolidation may precede further moves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
